September 6th, 2024
OUTBOUND PHARMA is pleased to announce that Kuljit Bhatia, Ph.D. has been appointed as Chief Scientific Officer. With over 27 years of executive experience in the pharmaceutical, biotech, and consumer health industries, Dr. Bhatia brings a wealth of expertise in research and development, CDMO leadership, and technical operations.
This appointment signifies a pivotal moment for OUTBOUND PHARMA as it aims to strengthn its scientific and commercial capabilities for its global clients, especially CMO/CDMOs and API manufacturers.
"I am delighted to welcome Dr. Kuljit S. Bhatia to the leadership team as our new Chief Scientific Officer. Dr. Bhatia's vast experience and proven track record in pharmaceutical innovation and leadership make him a tremendous asset to our team. His expertise in R&D, CDMO, and product commercialization will play a pivotal role in driving our mission forward." - Claudio Rota, CEO
Dr. Bhatia has a distinguished track record in leading R&D initiatives, overseeing the development and commercialization of over 12 NDAs and 75+ ANDAs. His expertise spans across multiple drug delivery systems, including semi-solids, oral solids, respiratory products, injectables, nasal sprays, ophthalmic solutions, and transdermal products. His ability to manage and execute complex projects from bench to commercialization will be invaluable as we continue to expand our offerings in the pharmaceutical space.
In addition to his R&D accomplishments, Dr. Bhatia has played pivotal roles in major M&A transactions, including the Fougera sale to Sandoz and the DPT sale to Mylan. His strategic vision and operational expertise in managing large, matrixed organizations make him a perfect fit for our leadership team as we aim to scale and strengthen our capabilities.
We are particularly excited about the new perspectives Dr. Bhatia will bring to Outbound Pharma, especially in enhancing our CDMO services and client management processes. His leadership will help us continue to offer top-tier services to our clients while driving efficiency and innovation across all aspects of our business.
Please join us in extending a warm welcome to Dr. Bhatia! We’re excited to see the impact his vision and expertise will bring to our growing company.
Outbound Pharma is a specialized lead generation and business development consultancy that empowers B2B life science businesses to achieve growth. Our core expertise lies in account-based sales and business development, all of which play pivotal roles in our effective lead generation campaigns. With a rich experience spanning over 7 years, we have consistently served as a reliable partner for B2B life science companies in their pursuit of generating BD opportunities. Our unwavering focus revolves around assisting sales and marketing teams in creating a steady stream of qualified leads. We are dedicated to continuously exploring innovative approaches to enhance lead generation for professionals in the industry.
コメント